帕洛诺司琼VS昂丹司琼.pdfVIP

Annals of Oncology 14: 1570–1577, 2003 Original article DOI: 10.1093/annonc/mdg417 Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron 1 2 3 4 5 6 7 R. Gralla , M. Lichinitser , S. Van der Vegt , H. Sleeboom , J. Mezger , C. Peschel , G. Tonini , 8 9 10 R. Labianca , A. Macciocchi M. Aapro * 1 2 3 New York Lung Cancer Alliance, New York, NY, USA; Cancer Research Center, Moscow, Russia; Ziekenhuis Ondenrijn, Van Heuven Goedhartlaan, Utrecht; 4Ziekenhuis Leyenburg, Den Haag, The Netherlands; 5St Vincentius-Kliniken, Karlsruhe; 6Klinikum rechts der Isar der Technischen Universität München, Munich, Germany; 7Oncology Department Campus, Bio-Medico University, Rome; 8 Ospedali Riuniti di Bergamo, Unitá Operativa di Oncologia Medica, Bergamo, Italy; 9Helsinn Healthcare SA, Lugano; 10IMO, Clinique de Genolier, Genolier, Vaud, Switzerland Received 10 June 2003; revised 17 July 2003; accepted 21 July 2003 Background: Although all first-generation 5-HT receptor antagonists demonstrate efficacy in preventing 3 acute chemotherapy-induced nausea and vomiting (CINV), effective preve